HSP90B2P and neoplasm: Initial investigations utilizing HSP peptide complex-96 (HSPPC-96), an HSP that can bind tumor-associated antigens, as a tumor vaccine revealed that this treatment was safe and there was significant peripheral immune response to the treatment (146).